Type of Deal: 100% acquisition through internal transfer between wholly owned subsidiaries
Stake/Capacity: 100% stake transfer
Deal Value: Approximately INR 29 crore (subject to adjustments as agreed between parties)
Funding Source: Cash consideration
Financial Impact:
Auro Pharma LLC recorded nil turnover for FY 2026, FY 2025, and FY 2024
Auroactive Pharma Private Limited recorded turnover of INR 701.3 million for FY 2026
Auropharm Overseas Limited recorded nil turnover for FY 2026
The transaction is not expected to have material financial impact as it is an internal reorganization
Timeline: 60-90 days subject to customary corporate and transfer formalities
Strategic Rationale: The proposed share transfer is undertaken as part of an internal reorganization exercise to streamline the holdings of the Russian subsidiary within the group companies.
Approval Status: Approved by the board of directors of the respective companies and Aurobindo Pharma Limited in its meeting held on November 4, 2026
Reference Regulation: SEBI Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III
Additional Details:
Auro Pharma LLC was incorporated on July 24, 2023, in Russia for manufacturing and marketing pharmaceutical products
The transaction qualifies as a related party transaction but is exempt from provisions of Regulations 23(2), (3) and (4) of SEBI LODR Regulations as it is between wholly owned subsidiaries
No governmental or regulatory approvals required
The transaction is being undertaken at arm's length price
